Pharmaceutical Technology

FEBRUARY 3, 2023

Since HIV integrates with the DNA, eliminating the virus from the body is very difficult, explains David Montefiori, PhD, director of the Laboratory for AIDS Vaccine Research and Development at Duke University in Durham, North Carolina. The failure of several late-stage trials highlights the challenging nature of HIV vaccine development.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

The Pharma Data

NOVEMBER 26, 2020

26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. Study will expand access to antibody testing outside of laboratory settings. DNA Link, Inc.

DNA 52

DNA Antibody Research Genomics 52

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 263

Antibody DNA Research Development 263

Pharmaceutical Technology

JULY 6, 2022

The researchers found evidence that antibodies are linked to an attack on the cells lining the blood vessels in the brain, causing inflammation and damage. The researchers also observed that antibodies produced in response to Covid-19 may wrongly act on cells vital to the blood-brain barrier.

Immune Response 162

Immune Response Antibody Gene DNA 162

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Transcription of the cap gene is initiated from a single promoter termed p40.

Gene 262

Gene Gene Therapy Genetics DNA 262

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 242

Antibody DNA Research Development 242

Pharmaceutical Technology

JUNE 4, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. bluebird bio is also developing drugs based on DNA and retro-virus vectors.

Gene Therapy 246

Gene Therapy DNA Gene Genetics 246

BioTech 365

SEPTEMBER 2, 2020

DNA Link’s Serology Test Showed High Degree of Sensitivity and Specificity for Detecting COVID-19 IgG Antibodies CHICAGO–(BUSINESS WIRE)–BASE10 Genetics, Inc.

DNA 40

DNA Antibody Genetics 40

Roots Analysis

DECEMBER 12, 2021

DNA data storage involves encoding and decoding binary data to and from synthesized strands of DNA. DNA data storage is an innovative technology that works by encoding large digital data sequences of binary form (0s and 1s) into DNA sequences (Adenine (A), Guanine (G), Cytosine (C) and Thymine (T)). DNA Storage.

DNA 52

DNA Research Engineer Marketing 52

Pharmaceutical Technology

MARCH 28, 2023

GSK’s trial evaluated the programmed death receptor-1 (PD-1)-blocking antibody Jemperli (dostarlimab). According to the National Cancer Institute, mismatch repair cells are “cells that have mutations in certain genes that are involved in correcting mistakes made when DNA is copied in a cell”.

DNA 130

DNA Clinical Trials Clinical Trials Trials 130

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

Gene Splicing 130

Gene Splicing Gene DNA Recombinant DNA Technology 130

Pharmaceutical Technology

DECEMBER 21, 2022

A CD19-directed antibody-drug conjugate, Zynlonta attaches to a CD19-expressing cell. The payload attaches to deoxyribonucleic acid (DNA) minor groove with minimum distortion, making it less noticeable to DNA repair mechanisms. This causes the stoppage of cell cycle and death of tumour cells.

DNA 130

DNA Clinical Trials Clinical Trials Medicine 130

Pharmaceutical Technology

NOVEMBER 3, 2022

Trial 1092 met the primary endpoint of the percentage of subjects with HBV deoxyribonucleic acid (DNA) levels less than 20 IU/ml following 24 weeks of treatment. At 24 weeks, 21% of the participants who received 25mg Vemlidy attained HBV DNA less than 20IU/ml versus 0% in the placebo arm.

DNA 130

DNA FDA Approval Clinical Trials Clinical Trials 130

Worldwide Clinical Trials

JUNE 21, 2024

This year, Matt Cooper, PhD , our Executive Director, Therapeutic Strategy Lead, Oncology, attended and found the presentations around antibody-drug conjugates (ADCs) and tumor-infiltrating lymphocytes (TILs) to be of great interest to the future of oncology therapeutics.

Antibody 162

Antibody Clinical Trials Clinical Trials In-Vitro 162

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

In-Vivo 162

In-Vivo Genomics Genome Gene Editing 162

XTalks

JANUARY 21, 2025

The liquid portion of the blood (serum or plasma) containing antibodies is separated and tested using the Liason Biotrin parvovirus B19 IgG plus test on a Liason XL analyzer. If parvovirus B19 antibodies are present, they bind to the chemicals and particular particles in the test, producing a light signal. Photo courtesy of BD.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

The Pharma Data

SEPTEMBER 11, 2021

Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R. Wood, Ph.D., About Twist Biopharma.

Antibody 52

Antibody DNA Containment Manufacturing 52

BioTech 365

JULY 28, 2021

Touchlight and Vanderbilt University Medical Center collaborate on DARPA Pandemic Prevention Platform programme to develop synthetic DNA-based antibody to protect against emerging threats Touchlight and Vanderbilt University Medical Center collaborate on DARPA Pandemic Prevention Platform programme to develop synthetic DNA-based … Continue reading (..)

DNA 40

DNA Antibody Development 40

XTalks

MARCH 17, 2025

This system captures and enriches circulating tumor cells (CTCs) and related biomarkers from patient blood samples using a physical, antigen-independent method offering an alternative to conventional antibody-based techniques.

Production 71

Production Manufacturing DNA Genetics 71

Pharmaceutical Technology

FEBRUARY 3, 2023

The established method for this process is a triple transfection using three different DNA plasmids. Moving the viral vector field closer to the monoclonal antibody field is really what we see as the way forward.” Most importantly, there is a need for stable producer cell lines growing in suspension.

Genomics 244

Genomics Genome Medicine Gene Therapy 244

BioTech 365

JUNE 7, 2021

Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in 100% of Trial Cohort Against B.1.1.7, 1.526 Variants and Sets August 2021 Mink Challenge Trial Launch Applied DNA Reports Veterinary COVID-19 Vaccine Candidate Induces Neutralizing Antibodies in … Continue reading →

DNA 40

DNA Antibody Trials Vaccination 40

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

In-Vivo 130

In-Vivo DNA Antibody Gene 130

Pharmaceutical Technology

JUNE 8, 2023

The partnership’s initial focus is to support drug developers to advance cell and gene therapies (CGT) using pioneering modalities including viral vectors (AAV, LVV, RV and HSV), antibodies (mAb, bsAb and ADC), CAR-T therapies and vaccines (DNA, mRNA and protein).

Gene Therapy 130

Gene Therapy Gene Development Antibody 130

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. In terms of application diversity, Eli Lilly is the top company, followed by C.

Genetics 130

Genetics DNA Genomics Genome 130

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. IgG antibody responses are a useful marker of antigen exposure to diagnose immunodeficiency.

Gene Expression 130

Gene Expression Gene Genetic Engineering Antibody 130

Pharmaceutical Technology

MAY 8, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

RNA 240

RNA Genetics Vaccine Vaccination 240

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Oligonucleotides is used to block the production of proteins needed for cell growth.

RNA 130

RNA DNA Antibody Production 130

BioTech 365

NOVEMBER 23, 2020

Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies Twist Bioscience Announces Positive Preclinical Data for SARS-CoV-2 Antibodies SOUTH SAN FRANCISCO, Calif.–(BUSINESS

Antibody 40

Antibody DNA 40

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Peptides have a longer shelf life due to their simplicity and ease of transport.

Antibody 130

Antibody DNA Production Medicine 130

BioPharma Reporter

JUNE 24, 2021

Iksuda Therapeutics, a developer of a new generation of antibody drug conjugates (ADCs), has expanded its research collaboration and license agreement with LegoChem Biosciences Inc (LCB).

DNA 55

DNA Licensing Licensing Antibody 55

Pharmaceutical Technology

MAY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Life Science 162

Life Science DNA Antibody Development 162

Pharmaceutical Technology

FEBRUARY 14, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Antibody 130

Antibody Vaccine Vaccination DNA 130

Pharmaceutical Technology

MARCH 1, 2023

The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The drug candidate is administered through the oral route in the form of capsule and tablet. It is a new chemical entity.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The drug candidate is administered through the oral route in the form of capsule and tablet. It is a new chemical entity.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Roots Analysis

JANUARY 21, 2024

With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. In this context, the role of the linker molecule and the conjugation technology used is pivotal.

Antibody 40

Antibody Recombinant DNA Technology Drugs Marketing 40

Pharmaceutical Technology

MARCH 9, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Sanofi and F. Hoffmann-La Roche are the other key patent filers in transgenic murine models.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

Pharmaceutical Technology

FEBRUARY 15, 2023

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely.

Vaccination 130

Vaccination Vaccine Protein Immune Response 130